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Abstract
Polymeric nanocapsules are versatile delivery systems with the capacity to load lipophilic drugs
in their oily nucleus and hydrophilic drugs in their polymeric shell. The objective of this work
was to expand the technological possibilities to prepare customized nanocapsules. First, we
adapted the solvent displacement technique to modulate the particle size of the resulting nano-
capsules in the 50–500 nm range. We also produced nanosystems with a shell made of one or
multiple polymer layers i.e. chitosan, dextran sulphate, hyaluronate, chondroitin sulphate, and
alginate. In addition, we identified the conditions to translate the process into a miniaturized
high-throughput tailor-made fabrication that enables massive screening of formulations. Finally,
the production of the nanocapsules was scaled-up both in a batch production, and also using
microfluidics. The versatility of the properties of these nanocapsules and their fabrication tech-
nologies is expected to propel their advance from bench to clinic.
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1 | INTRODUCTION
Nanocapsules (NCs) are nanometric systems with an inner core and
an external shell. Depending on their composition, NCs have been
named as lipid NCs, consisting of an oily core stabilized by PEGylated
amphiphilic molecules; and polymeric NCs, when the oily nucleus is stabi-
lized by a polymeric shell. Al-Kouri et al. described in 1986 the first poly-
meric NCs, made of polyisobutylcyanoacrylate (PACA).1 In 1989, Fessi
et al. reported the preparation of poly-(D,L-lactide) (PLA) NCs by the
solvent-displacement technique.2 Subsequently, our group extended the
application of this technology to the production of NCs with a
hydrophobic shell, that is, poly-ε-caprolactone (PCL) NCs,3–5 and a vari-
ety of hydrophilic polymer shells consisting of chitosan (CS),6 hyaluronic
acid,7 poly-L-asparagine,8 polyglutamic acid,9 polyarginine,10 and
protamine.11
Due to their lipidic core, NCs were, originally, conceived as suit-
able carriers for lipophilic drugs. However, our lab has expanded this
technology to allow NCs to carry hydrosoluble macromolecules, such
as proteins,12,13 peptides,14–16 and polynucleotides,10 using them in
different therapeutic areas. For example, in the oncology field, we
have developed different polymeric NCs containing the cytotoxic
drugs plitidepsin and docetaxel,10,17–21 which were able to prolong
the blood circulation time of these drugs and reduce their toxicity. In
addition, an important accumulation of the drugs in the lymphatic sys-
tem was observed. In the vaccinology field, we have successfully associ-
ated different types of protein antigens, such as tetanus toxoid,13
influenza antigen,22 recombinant hepatitis B surface antigen,23 and IutA
E. coli antigen24 to different NCs. The overall result observed, when
using these antigens, was an increased immunogenic response following
either, intramuscular or intranasal immunization. Finally, we have also
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found that polymeric NCs can increase the bioavailability of different
drugs administered through different mucosal routes. For example, our
results have shown the possibility of increasing the corneal penetration
of drugs associated to the NCs.6,25 Similarly, we have found that poly-
meric NCs led to an enhancement of the systemic absorption of peptide
and protein drugs administered by the oral11,15,16 or nasal14,26 routes.
Apart from these uses, and due to their versatile nature,
NCs have also been loaded with compounds with different
activities: anti-inflammatory,27–29 antibacterial,30,31 antifungal,32–35
antioxidant,28,36,37 and immunosuppressant,38 among many others.39
Besides the solvent-displacement technique, two other widely
used NCs preparation methods are the high energy-homogenization
and the phase inversion temperature method.40–43 In general, it is
known that the ratio between the different phases (solvent and
nonsolvent),39 the type of oil and polymers used, and their relative
concentration44 may influence the size and surface properties of NCs
obtained by solvent displacement. However, the influence of other
technological parameters, such as the way and rate of mixing of the
two phases has not been systematically investigated. A better under-
standing of the impact of these variables would allow a more precise
control over the particle size when engineering NCs. On the other
hand, a combination of the solvent-displacement technique with the
layer-by-layer approach offers interesting possibilities to modify the
NCs surface properties and, hence, to influence the stability of the
NCs and their interaction with the biological systems. Moreover, the
nature of the multiple shell polymers may facilitate the loading of dif-
ferent drugs, and their controlled release.24,45,46
Taking all this into consideration, our goal in this study was to
design formulation and technological approaches to produce tailor-
made polymeric NCs, and to do so according to different scale-down
(microliters) and scale-up (liter) techniques. The knowledge generated
during these studies will hopefully contribute to a more straightfor-
ward translation of polymeric NCs from bench to clinic.
2 | MATERIALS AND METHODS
2.1 | Materials
2.1.1 | Oils
DL-α-Tocopherol (Calbiochem) and squalene (density: 0.855 g/mL)
were obtained from Merck Millipore (Darmstadt, Germany). Miglyol
812 was kindly gifted by Cremer Oleo GmbH & Co. KG (Hamburg,
Germany).
2.1.2 | Surfactants
Deoiled phosphatidylcholine-enriched L-α-lecithin (Epikuron 145 V)
was a gift from Cargill (Barcelona, Spain). Poloxamer 407 (Pluronic
127) was obtained from BASF (Ludwigshafen, Germany). D-
α-Tocopherol polyethylene glycol 1,000 succinate (TPGS) was
purchased to Antares Health Products Inc. (Jonesborough, TN).
Polyethylene glycol sorbitan monooleate (Tween 80), hexadecyltri-
methylammonium bromide (CTAB), and sodium cholate hydrate
were purchased from Sigma-Aldrich (St. Louis, MO).
2.1.3 | Polymers
Ultrapure CS hydrochloride salt (Protasan UP CL 113, Mw 125 kDa,
deacetylation degree of 86%) was purchased from Novamatrix
(Sandvika, Norway). Dextran sulfate sodium salt (Mw 6–8 kDa) was
bought to MP Biomedicals (Illkirch, France). For the preparation of the
NCs in the 96-well plate pharmaceutical grade CS hydrochloride with
a Mw of 47 kDa and a 80–95% deacetylation degree was acquired
from Heppe Medical Chitosan GmbH (Halle, Germany), and dextran
sulfate sodium salt pharmaceutical grade, with a Mw 8 kDa was pur-
chased from Sigma-Aldrich SAFC (Madison, WI). Polyarginine
(Mw 29 kDa was obtained from PTS (Valencia, Spain). Sodium alginate
ULV-L3 (viscosity 10% solution 27 mPas) was purchased from Kimica
Corporation (Tokyo, Japan). Carboxymethyl-β-glucan sodium salt,
obtained from Saccharomyces cerevisae and modified with carboxy-
methyl groups at an 85% substitution degree, was a kind donation
from Mibelle AG Biochemistry (Buchs, Switzerland). Sodium hyaluro-
nate (HA; Mw 57 kDa) was purchased from Lifecore Biomedical
(Chaska, MN). Poly-L-glutamic acid sodium salt (Mw 15–50 kDa), and
chondroitin-6-sulphate sodium salt were obtained from Sigma-
Aldrich.
2.1.4 | Others
All other chemicals used were of reagent grade or higher purity.
2.2 | Design of experiments
The Statgraphics Centurion XVI.I software was used to design the
experiments. Two response variables (size and polydispersity index
[PDI]) and three experimental factors: (a) rate of addition of the
organic phase over the aqueous phase (pouring vs. injection),
(b) volume of the organic phase (ethanol volume from 0.25 to 5 mL),
and (c) volume of aqueous phase (from 5 to 15 mL) were specified. A
factorial 23 design was performed, with four centerpoints per block
and a random centerpoint placement. The selected design had 12 runs,
with one sample to be taken each run. The default model was 2-factor
interactions with seven coefficients.
Regarding the experimental procedure, the NCs were prepared by
the solvent-displacement technique, using a modification of the
method previously developed by us.47 Briefly, an organic phase con-
taining 30 mg of vitamin E and 10 mg of lecithin in the required
amount of ethanol was added over an aqueous phase containing 5 mg
of CS in the required amount of water. After the addition of the
organic phase over the aqueous phase by either the pouring or the
injecting procedure the sample was stirred at 300 rpm for 10 min.
Finally, without removing the solvent, size and PDI were measured by
dynamic light scattering (DLS).
2.3 | NCs preparation by either pouring or injecting
the organic phase over the aqueous phase
The organic phase of these formulations consisted of 0.5 mL solution
of the oil (60 mg/mL) and 0.5 mL of the surfactant (20 mg/mL), both
in ethanol. In those cases where a co-surfactant was included, 25 μl of
an aqueous solution of this component (sodium cholate 200 mg/mL
or CTAB 66.67 mg/mL) were added. Finally, the volume was adjusted
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with pure ethanol up to 2.5 mL. The aqueous phase was prepared dis-
solving 5 mg of the polymer in 10 mL of ultrapure water, or just water
for nanoemulsions. The addition of the organic phase over the aque-
ous phase was made in two different ways: by pouring one phase over
the other or by injecting the organic phase inside the aqueous phase
through a needle (100 Sterican,  0.60 × 60 mm, 23G × 23/800, Braun,
Melsungen, Germany) applying high manual pressure. In both cases,
the aqueous phase was maintained under stirring during the addition.
After 10 min of agitation at 300 rpm, samples were characterized
by DLS.
2.4 | Preparation of larger sizes NCs
The solvent-displacement technique was readjusted to modulate the
NCs particle size. Thus, 0.5 mL of a solution of vitamin E 60 mg/mL
and 0.5 mL of a solution of lecithin 20 mg/mL, both in ethanol, were
mixed in a test tube. Upon stirring at 700 rpm, an initial volume of
water was added with a micropipette. The emulsion was maintained
under these conditions for a specific time. After that time, 4 mL of an
aqueous solution of CS 1.25 mg/mL were added, and the suspension
stirred for 10 min. Finally, the NCs were characterized by DLS.
2.5 | Layer-by-layer coating of NCs
Different volumes of NCs were placed in glass HPLC vials. To these
samples, and under stirring at 300 rpm, different volumes of a second
polymer solution were added up to a total of 1 mL, while keeping the
ratio polymer layer 1:polymer layer 2 (w/w) constant. The mixture
was stirred for 30 min and characterized by DLS. Once the ratio of
volumes was selected, a fixed volume of NCs was placed in a glass
HPLC vial. To this solution, and under stirring at 300 rpm, a fixed vol-
ume of a second polymer solution was added up to 1 mL, testing dif-
ferent ratios polymer layer 1:polymer layer 2 (w/w). The mixture was
stirred for 30 min and then characterized by DLS. This procedure was
repeated for each consecutive layer.
2.6 | NCs preparation by a high-throughput
screening-adaptable procedure
NCs composed of different materials (Supporting Information
Table S1) were prepared adapting the solvent-displacement method
to a 96-multiwell plate. Briefly, an organic phase was prepared mixing
50 μl of a 72 mg/mL ethanolic solution of the selected oil, 40 μl of a
37.5 mg/mL ethanolic solution of the surfactant, and 10 μl of the co-
surfactant solution (if needed). As a co-surfactant an aqueous solution
of sodium cholate 30 mg/mL or CTAB 10 mg/mL were used for posi-
tive and negatively charged NCs, respectively. For the NEs and the
combinations containing a positive polymer and lecithin, or a positive
polymer and squalene, the co-surfactant was not included. The
organic phase was poured with a micropipette into the corresponding
well of a 96-multiwell plate containing 200 μl of 1.5 mg/mL aqueous
solution of the polymer or just water in the case of NEs. The addition
was made under horizontal shaking (300 rpm) and samples were incu-
bated for 10 min before characterization by DLS.
2.7 | Preparation of NCs with different volumes of
ethanol
About 30 mg of vitamin E and 10 mg of lecithin were dissolved in dif-
ferent volumes of ethanol. This solution was added over 10 mL of an
aqueous solution of CS (0.5 mg/mL). The addition was done by either
pouring the organic phase over the aqueous phase or by injecting it
through a needle (100 Sterican,  0.60 × 60 mm, 23G × 23/800, Braun,
Melsungen, Germany) applying high manual pressure. In both cases,
the aqueous phase was maintained under stirring. After 10 min of agi-
tation at 300 rpm, the excess of ethanol was removed using a rotary
evaporator (Büchi, Switzerland) and the volume was adjusted to 5 mL
with ultrapure water.
2.8 | Batch scale-up of NCs
For a 100 mL batch, an organic solution was prepared mixing 2 mL of
lecithin 50 mg/mL and 0.5 mL of vitamin E 600 mg/mL both in etha-
nol. The final volume was adjusted with ethanol to 10 mL. This solu-
tion was poured into 100 mL of an aqueous solution of CS 0.5 mg/mL
under agitation at 500 min−1, using a propeller stirrer IKA RW
20 (Staugen, Germany; 4-bladed, stir diameter 50 mm, shaft diameter
8 mm, and shaft length 350 mm).
For a 1 L batch, an organic solution containing 1 g of lecithin and
3 g of vitamin E in 100 mL of ethanol was prepared. This solution was
poured into 1 L of an aqueous solution of CS 0.5 mg/mL under agita-
tion at 500 min−1, using a propeller stirrer IKA RW 20 (Staugen, Ger-
many; 4-bladed, stir diameter 10 cm, shaft diameter 8 mm, and shaft
length 350 mm). After 10 min of stirring sample was characterized
by DLS.
2.9 | NCs preparation by microfluidics
A NanoAssemblr Benchtop (Precision nanosystems, Vancouver,
Canada) system was used to prepare the NCs. The cartridge channels
dimensions were 200 μm wide and 79 μm high, with herringbone
structures formed by 31 μm high and 50 μm thick in the mixer area. To
check the influence of the total flow rate this flow was varied from 2.5
to 15 mL/min. The organic phase was a mixture of 0.5 mL of vitamin E
60 mg/mL and 0.5 mL of lecithin 20 mg/mL, both in ethanol. The aque-
ous phase was prepared by dissolving 5 mg of CS in 9 mL of water. The
total concentration in this case was 4.5 mg/mL. To check the influence
of the components concentration, a total flow rate of 10 mL/min was
selected. While the ratio of the components was constant, their con-
centration varied from 2.25 mg/mL to 22.50 mg/mL. After the samples
were prepared, their particle size and PDI was characterized by DLS.
2.10 | Physicochemical characterization
Particle size and polydispersity index by DLS using a Zetasizer Nano-S
(Malvern Instruments; Malvern, UK). Zeta potential was determined
by laser Doppler anemometry, using the same equipment. If not indi-
cated, analyses were performed at 25 C with a detection angle of
173 in distilled water.
The morphology of the NCs was examined by field emission scan-
ning electron microscopy (FESEM; ZEISS, ULTRA Plus, Germany). For
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the analysis, the NCs were diluted in water 1:1000 and mixed with
the same volume of 2% (w/v) phosphotungstic acid solution. A volume
of 1 μl of this mixture was placed on copper grids with carbon films.
The grids were left to dry in the open air and then they were washed
with 1 mL of water. Once the grids were dried they were observed in
the microscope using both STEM and immersion lens (In-Lens)
detectors.
2.11 | Statistical analysis
Unless otherwise indicated, the experiments were repeated at least
three times. The results are presented as mean  SD. For the compar-
ison of the NCs particles sizes by pouring or injecting the organic
phase over the aqueous phase (section 3.1.1) a multiple t test was per-
formed meanwhile for the comparison of the particles sizes in
section 3.1.2 a one-way ANOVA was performed. The differences were
considered significant for * p < .05, ** p < .01, *** p < .001, and ****
p < .0001. All the statistical analyses were carried out with GraphPad
Prism Version 6.0 software (GraphPad software Inc., La Jolla, CA).
3 | RESULTS AND DISCUSSION
Polymeric NCs can be easily prepared using the solvent-displacement
technique (Supporting Information Figure S1). The lipids are dissolved
in a solvent phase (also referred to as organic phase), which spontane-
ously forms NCs when poured into a nonsolvent phase (usually an
aqueous phase). Molecules that were soluble in the solvent phase
exceed their thermodynamic solubility limit when the solvent and
nonsolvent phases mixes, which results in the formation of oily nano-
droplets. Simultaneously, the polymer solubilized in the aqueous
phase gets adsorbed onto the oily droplets surface due to its electro-
static interaction with surfactants of opposite charge. Finally, the
excess of organic solvent, if any, is eliminated by evaporation.
From a technological point of view, it is crucial to have versatile
methods that enable the control of the nanosystem’s size, as this
property is known to influence their interaction with the biological
systems.48–50 Moreover, from a quality control point of view, the
accuracy of this parameter is essential for the high scale production
and the clinical development of a formulation. Having this in mind, in
this study, we have studied systematically the influence of the compo-
sition and technological parameters on the size of NCs prepared by
the solvent-displacement technique.
3.1 | Modification of the NCs particle size
3.1.1 | Preparation of NCs with particle size <100 nm
The production of nanosystems with particle sizes smaller than
100 nm may be of interest for specific applications. For example, in
the area of oncology, a small size is critical for improving the penetra-
tion across the tumor.51,52 Similarly, in vaccinology, the small size may
favor the lymphatic drainage.53,54
Previous studies by our research group showed that the dilution
of Miglyol 812 and lecithin in the organic phase, and the dropwise
addition of this phase over an aqueous one lead to a significant
decrease in the average size of the obtained oily nanodroplets, from
~200 to 100 nm.55 Based on this result, we adopted an experimental
design in which we kept constant the mass and ratio of the NCs com-
ponents, and we varied the following parameters: (a) the volume of
the organic phase (ethanol), (b) the volume of the aqueous phase, and
(c) the way the organic phase was added over the aqueous phase
(pouring vs. injecting). As a standard NC composition, we chose one
previously reported by our group that consisted on a combination of
CS and vitamin E with lecithin as a surfactant.24 The response surface,
presented in Figure 1, shows that the smallest particle sizes were
obtained with the highest volumes of ethanol (5 mL) and water
(15 mL), confirming that, as expected, the dilution of lipophilic and
hydrophilic components in their respective phases favors the forma-
tion of smaller particle sizes. On the other hand, the injection of the
organic phase inside the aqueous phase through a needle has a clear
impact in the NCs particle size when compared with the technique
consisting on just pouring one phase over the other, even when the
concentration of the starting solutions remains the same. The addi-
tion, in both cases, is quite fast.
The molecular mechanisms behind the nanodispersion achieved
by the solvent-displacement technique have been attributed to inter-
facial turbulences between the solvent and nonsolvent phases, known
as the Marangoni effect, which leads to the separation of the system
into two phases.56,57 Other authors attribute the formation of the
NCs to a simultaneous process of emulsification driven by the “ouzo
effect”58,59 and polymer deposition over the oily nanodroplets. In the
case of polymeric NCs, this means that the local supersaturation of
the oil drives a spontaneous nucleation in the form of small oily nano-
droplets. The already formed nuclei grow by aggregation or by diffu-
sion of oil molecules from the surroundings. The growth continues
until the oil concentration reaches the equilibrium saturation concen-
tration.60 Experimentally, to obtain small particles sizes, we should
favor rapid nuclei formation and little or no particle growth. This can
be achieved, as indicated in Figure 1, by decreasing the concentration
of the oil, to avoid particle growth, and/or injecting the nonsolvent
into the solvent phase, which produces turbulences that create multi-
ple small nuclei of oily nanodroplets.
Considering that, with a simple injection of the organic phase over
the aqueous phase, the NCs particle size could be efficiently reduced,
we wanted to know whether this result was composition-dependent.
To do so, we tested different combinations of components from a
panel of nanosystems (Figure 2b). Positive and negative nanoemul-
sions (NEs) and NCs were prepared either by pouring or by injecting
the organic phase over the aqueous phase (Figure 2a), at a fixed con-
centration of the components.
A considerable reduction in the particle size was observed for all
the formulations when using the injection method (between 50 and
115 nm of size variation; Figure 2c). For lecithin/squalene NE (NE 4),
this decrease was particularly obvious, with a drop in the particle size
from 171  3 to 56  7 nm. This decrease in size was also noticeable
when the particles were analyzed by electron microscopy (Figure 2a).
However, it is important to mention that the formulations obtained
through injection tended to have slightly higher polydispersity index
(PDI), especially for NEs, a fact that reflects the stabilizing property of
the polymer shell.
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3.1.2 | Preparation of NCs with particle size >400 nm
In the same way that there is a reduction in the size of the NCs when
the concentrations of their components in the organic and the aque-
ous phases are decreased, when their concentrations are higher there
is a substantial increase in the NCs size. However, with the standard
preparation protocols, there is a limit beyond which, aggregation
and/or free oil are observed. In our hands, particle sizes higher than
400 nm were difficult to achieve with the previously reported proce-
dures. To obtain higher particle sizes, we developed a new 2-step
method for the preparation of NCs consisting of CS/lecithin/vitamin
E. The method is described as follows.
3.1.2.1 | Formation of an unstable nanoemulsion
After the addition of a small volume of water to a concentrated solu-
tion of lecithin and vitamin E in ethanol, the spontaneous formation of
a dynamic colloidal system was observed. The system evolved during
the first 2 min giving rise to an increase in the particle size and, even-
tually, to the formation of macroscopic oily droplets, probably due to
the concentration and the size of the formed nanodroplets.
3.1.2.2 | Stabilizing the nanoemulsion
After the addition of water to the organic phase and, prior to the
aggregation phase (within the first 2 min), the system could be stabi-
lized by adding a second, and larger, volume of water containing
CS. By adjusting the elapsed time between the addition of the initial
volume of water added to the ethanolic phase and the addition of the
polymer solution, it was possible to modulate the NCs particle size in
the 200–500 nm range.
To evaluate the influence of the initial volume of water added to
the organic phase, (step 1, Figure 3a), the elapsed time between the
initial addition of water and the addition of the CS solution was kept
constant. The results showed that when the initial volume was small
(0.1–0.2 mL) compared with the ethanol volume (0.5 mL), the oil
remained solubilized in the mixture and only after adding a second
and larger volume of polymer aqueous solution (steps 2–4), NCs with
a size in the 250–350 nm range were formed. When the initial volume
of water increased up to 0.3–0.5 mL, we detected the formation of
large nanodroplets, which after the addition of the CS aqueous
solution produced stable NCs with average particle sizes between
400 and 500 nm. Finally, when the initial volume of water in step
1 was ≥0.6 mL, the size of the NCs was similar to those obtained with
the previously reported preparation procedures (around 350 nm). In
Figure 3b, the particle sizes of the obtained NCs by this procedure are
compared with the standard protocol of NCs preparation, with only one
addition of water with the polymer dissolved in it over the organic phase.
On the other hand, the elapsed time between the two additions
of water is also crucial because of the dynamic nature of the resulting
nanoemulsion, as discussed before. For that reason, time is another of
the variables that can be used to modulate the final particle size, being
a 30–60 s range appropriate to obtain particles sizes larger than
300 nm (Figure 3c).
3.2 | Layer-by-layer surface modification of NCs
Besides their particle size, the surface charge and composition of the
nanosystems are also important parameters that influence their final
fate in vivo.61,62 In this regard, the layer-by-layer (LbL) technique
allows the modification of the nanosystem’s surface and the incorpo-
ration of new compounds in the formulation.63–65 We previously
reported the interest in combining the LbL technique with the
solvent-displacement method, to produce bilayer dextran sulphate
(DS)-CS NCs for antigen protection and a controlled delivery.24 The
goal of the following experiments was to assess the applicability of
the assembling process to a variety of polymers (bilayer NCs), and to
determine the maximum number of layers that can be assembled
around the oily cores (multilayer NCs).
3.2.1 | Bilayer NCs
CS/lecithin/vitamin E monolayer NCs, used as a model template, were
incubated with different ratios of sulfated and carboxylated polya-
nions: hyaluronate (HA), alginate (Alg), and chondroitin sulfate (ChS)
(Figure 4a). The coating with a bilayer is considered effective when an
inversion in the ζ-potential occurs, which indicates that the positive
charge of CS has been completely masked by the negative charges of
the polyanion. The mass/mass ratio at which this inversion happens
is, ultimately, determined by the relative charge of the second poly-
mer. In the case of the tested polymers, the charges per monomer at
FIGURE 1 Response surface indicating the impact of different parameters on the nanocapsules particle size. The volumes of both the organic
and aqueous phase, and the way the first phase was added over the second (by pouring or injecting through a needle) were varied. The particle
size of the resulting nanocapsules was plotted against these three parameters (a). In (b), the influence of the aqueous phase volume and the rate
of addition over the particle size were represented. The volume of organic phase was kept constant at 5 mL in this case
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pH = 7 are: HA (0.5) < Alg (1) = ChS (1). These charges explain why
with a small amount of ChS (ratio CS:ChS 1:0.25), an important inver-
sion in the ζ-potential was already observed (Figure 4b), an inversion
similar to the one found with Alg (ratio CS:Alg 1:0.25) (Figure 4c), and sig-
nificantly smaller compared with the needed amount of HA (ratio CS:HA
1:1) (Figure 4d). These results are in agreement with those previously
reported for the bilayer CS/DS where a ratio CS:DS of 1:0.1 inverted the
ζ-potential,24 due to the high negative charge per monomer of DS (2.3).
3.2.2 | Multilayer NCs
Multilayer NCs can increase the formulation load, and modify or delay
the release of drug through the multiple polymeric shells. Based on
the bilayer NCs described above, we extended this methodology to
the engineering of multilayer NCs. Santos et al. followed a similar
approach using a washless LbL polyelectrolyte assembly to encapsu-
late low solubility drugs.66 In their case, the deposition of the poly-
mers was assisted by sonication. This could be a problem when
working with labile biomolecules. The group of Prof. Benoit, an expert
in lipid NCs,67,68 developed multilayer CS/DS NCs (6 layers) using the
phase inversion method, which needed a purification step by tangen-
tial flow filtration between the deposition of each layer.46 Our goal
was to determine the maximum number of layers that could be built
over the oily core, without purification steps, and without high-energy
inputs that could denature labile molecules.
In the process of engineering a multilayer NC, the key parameter
to be considered was the mass ratio between the polymers with
100 – 200 nm
Sample Polymer Surfactant Co-surfactant Oil
NE 1 - Lecithin - Vitamin E
NE 2 - TPGS Sodium cholate Vitamin E
NE 3 - Tween® 80 - Vitamin E
NE 4 - Lecithin - Squalene
NE 5 - Lecithin - Miglyol® 
812 
NE 6 - Lecithin CTAB Vitamin E
NC 1 Alginate Lecithin CTAB Vitamin E
NC 2 Hyaluronate Lecithin CTAB Vitamin E
NC 3 Chitosan Lecithin - Vitamin E
NC 4 Polyarginine Lecithin - Vitamin E
(b) (c)
(a) Pouring Injection



















































40 – 100 nm
FIGURE 2 Reduction of the nanocapsules particle size following the injection of the organic phase over the aqueous phase. The injection of the
organic phase inside the aqueous phase in the preparation of nanoemulsions (NEs) and nanocapsules (NCs) by the solvent-displacement
technique remarkably reduced the particle size compared with just pouring one phase over the other. FESEM images, using STEM (i) and InLens
(ii) detectors, of the CS/lecithin/vitamin E NCs prepared by the two methods. Scale bar 200 nm. (a) Different combination of oils, surfactants and
polymers were tested to produce NEs and NCs upon pouring or injecting the organic phase over the aqueous phase. (b) Differences in the particle
size of the NCs and NEs obtained with this modification in the preparation procedure are shown in C. ** and *** denote significant differences
between samples (p < .01 and p < .001, respectively)
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opposite charges (CS and DS). This mass ratio had to be empirically
calculated to ensure an efficient coating with the minimum amount
possible of free polymer.24 We did this to avoid the presence of any
soluble polymer in the colloidal suspension that could contribute to
the formation of undesired subpopulations of polymeric nanocom-
plexes, through the interaction with the polymer added to build the
next layer. Other important parameter to consider was the ratio
between the volume of the NCs suspension and the polymer solution
added to form the new layer (Supporting Information Figure S2).
Using this technique, up to 5 layers of polymers could be built over
the NE, without the need of purification steps (Figure 5a,c). The cho-
sen ratio DS:CS was 0.5:1 for the first two layers, for the third (CS),
fourth (DS), and fifth (CS) layers the ratio polymer:CS-first-layer was
1:1 with a final ratio CS5th/DS4th/CS3rd/DS2nd/CS1st 1:1:1:0.5:1. An
inversion of the ζ-potential was observed with each new polymer
layer added: from highly positive, when the CS was in the external
layer, to highly negative, when the DS was the external polymer
(Figure 5d). Moreover, the addition of CS increased the particle size
when it coated the NE or NCs, as expected. On the contrary, DS
slightly reduced the particle size when added over CS NCs, probably
because its highly negative charge caused a contraction of the
polymers.
3.3 | Scale-down of the NCs preparation: A high-
throughput screening-adaptable procedure
The high-throughput screening (HTS), using robotics and automatic
processes, has allowed the production and testing of a huge number
of compounds in a very short period of time,69–71 leading to unprece-
dented advances in the pharmacology field.72 Apart from saving time,
a HTS-adaptable procedure allows the preparation of multiple nano-
systems at once, with different composition or ratio between compo-
nents, thus multiplying exponentially the possibilities of success when
screening nanosystems.
In this study, a 96-multiwell plate was used to prepare NCs in a






































































FIGURE 3 Preparation method of nanocapsules with particle sizes > 400 nm. Schematic representation of the procedure to prepare
nanocapsules with a particle size >400 nm. This method consists of two steps: In a first step, a dynamic nanoemulsion is formed by adding a small
volume of water over an organic phase; in a second step, the primary nanoemulsion is diluted with a larger volume of a polymer aqueous solution
to form stable nanocapsules. FESEM images, using STEM (i) and InLens (ii) detectors, of the resulting nanocapsules. Scale bar 200 nm (a).
Influence of the initial volume of aqueous phase in the final particle size of the nanocapsules (b). Evolution of the nanoemulsion particle size after
the initial volume of water was added, showing its dynamic nature (c). # Indicates the presence of large particles in some replicates, ## indicates
the presence of large particles in all replicates
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Hyaluronic acid Alginic acid
Chondroitin sulphate
R1= SO3H;  
R2,R3 = H
FIGURE 4 Screening of the ratio of positive: negative polymer used to prepare bilayer nanocapsules. (a) Structure of the different
polysaccharides used to prepare bilayer nanocapsules of chitosan (CS) and sodium hyaluronate (HA) (b), Sodium alginate (Alg) (c), and sodium
chondroitin sulphate (ChS) (d) in their acid form. Dot line indicates neutral ζ-potential
(a) (b)
(c) (d)
FIGURE 5 Screening of different chitosan: dextran sulphate polymer ratios to study the formation of multilayer nanocapsules. Different chitosan
(CS)/dextran sulphate (DS) ratios were used to form the bilayer nanocapsules (NCs) (a). For the following layers, the mass ratio referred to the
first layer of CS was varied to form the third-layer and fourth-layer of NCs (b and c, respectively). The fifth layer was achieved directly using a
ratio 1:1 between the CS of the first and fifth layers. For the rest of the layers the ratio of election is indicated with the striped bar. Evolution of
the particle size and ζ-potential depending on the number of layers (d)
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this purpose, a selection of 3 different oils, 4 surfactants, 2 co-surfac-
tants, and 7 polymers were combined to produce 12 different NEs
and 84 different NCs in the same multiwell plate (Figure 6). Such an
on-demand screening of formulation conditions has never been
reported before. Taking into consideration that some of the tested
compounds are present in marketed vaccines (such as vitamin E, squa-
lene, and Tween 80),73 and that most of the polymers have shown
immunostimulant properties when associated to antigens in a nano-
particulated form,74 we envisage that these nanoformulations might
have a real potential as nanovaccines once loaded with the required
antigen.
Apart from showing the feasibility of miniaturizing the NCs prepa-
ration procedure, and thus facilitating a fast screening of multiple
nanosystems at the same time, this experiment allowed us to draw
some conclusions that are rather specific for the nanosystems
described here (Supporting Information Table S1). For example,
although most of the nanosystems had a particle size between
150 and 250 nm, squalene NEs/NCs tended to have larger sizes and,
in some cases, a wider distribution (PDI > 0.3). The combination of
vitamin E in the oily core and poloxamer 407 (P407) as a surfactant
rendered the smallest nanosystems. On the other hand, NCs with car-
boxymethyl beta glucan (CM-β-glucan) as polymer tended to have
larger sizes and higher PDI.
3.4 | Scale-up of the NCs preparation
The standard procedure for the preparation of NCs by solvent dis-
placement usually involves an organic phase, frequently ethanol, at
half the volume of the water phase;39 however, our results show that
reducing the percentage of ethanol from 33.33% to 4.76%, did not
affect the stability of the NCs (Supporting Information Figure S3).
Apart from minimizing/avoiding the use of solvents, another challenge
the industry faces when developing a nanoformulation is the
(a)
(b)
Vitamin E Squalene Miglyol 812
TPGS T80 Lec P407 TPGS T80 Lec P407 TPGS T80 Lec P407
- - - -- 0 - 0 -- - 0 0 -- 0
Polyarginine ++ ++ ++ ++ + 0 ++ + 0 0 ++ ++
Chitosan + + ++ + 0 0 ++ + + 0 ++ +
Hyaluronate -- -- -- - -- -- -- -- -- -- - --
Dextran
sulphate - - -- - -- -- -- -- -- -- -- --
Alginate -- -- -- -- -- -- -- -- -- -- -- --
Polyglutamate -- -- -- - - - -- - - - -- --
CM-β-glucan -- -- -- -- - -- -- -- - - -- --
Particle size Zeta potential
< 150 nm ++ > +30 mV
150 – 200 nm + +10 – +30 mV
200 – 250 nm 0 +10 – -10 mV
250 – 300 nm - -10 – -30 mV










































Vitamin E Squalene Miglyol 812 
CTAB 
FIGURE 6 Miniaturization of the nanocapsules preparation procedure in an adaptable-HTS method. Different combinations of polymers, oils,
and surfactants were used to prepare a variety of nanocapsules in a 96-multiwell plate (a). A schematic representation of the particle size and
ζ-potential of the resulting nanosystem (b). CM-β-glucan: Carboxymethyl-β-glucan, T80: Tween 80, Lec: Lecithin, P407: Poloxamer 407, CTAB:
Cetyl trimethylammonium bromide
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scalability of the technology.75 In this study, we investigated the pos-
sibility of scaling-up the formulation both by a discontinuous and a
continuous method.
3.4.1 | Batch production process
Thomas and his co-workers scaled-up the fabrication of lipid NCs by
phase inversion temperature up to approximately 870 mL, by increas-
ing the amount of the components and using special reactors.76 With
this in mind, we scaled-up the production of polymeric NCs by
increasing the volume of both phases, while maintaining the concen-
tration of the reagents, and substituting the magnetic stirring for
mechanical stirring, which is a more controllable way of mixing larger
volumes of liquids. First, we increased the water volume from 10 mL
to 100 mL (10×), and then, to 1 L (100×). The results shown in
Figure 7a indicate that the particle size, PDI, and ζ-potential were
maintained in the scaled-up batches. Interestingly, we also found that
when using large volumes of water, the volume of the organic phase
could be reduced without any change in the physicochemical proper-
ties of the final product. More specifically, for small volumes, we used
a 33.33%, v/v ethanol, while for 100 mL and 1 L batches we were
able to reduce this percentage to 9%. This result is particularly impor-
tant as this amount of ethanol could be acceptable in a final product
and, therefore, these conditions would preclude the need for solvent
evaporation at the end of the process. Besides, this batch production
technique might also be susceptible of incorporating alternative mix-
ing strategies77,78 for very large scale production.
3.4.2 | Production of NCs by microfluidics
Microfluidics has been applied to the preparation of different types of
nanosystems, such as metallic nanoparticles,79 polymer
nanoparticles,80 and liposomes,81 among others. However, to the best
of our knowledge, it has never been used to produce polymeric NCs.
The continuous flow guarantees the same quality over time, and the
adjustable parameters allow the control of the final system character-
istics. Moreover, microfluidics offers interesting possibilities for
scaling-up. However, this technique still faces some limitations mainly
due to the incompatibility of some devices with solvents, high temper-
atures and sticky materials, and its higher cost when compared with
the batch production.82
We used the CS/vitamin E NCs as a model system to be prepared
by this technique. Both phases, organic and aqueous, were pumped
into the cartridge while keeping a controllable flow. Inside the car-
tridge the two phases were mixed, by passing through a mixing area
(Figure 7b). We kept constant the amount of each component to have
a final concentration of NCs of 4.5 mg/mL. Then, we varied the flow,
observing that, the higher the total flow rate, the smaller the NCs par-
ticle size (Figure 7c). The size decreased from more than 200 nm, at a
flow rate of 2.5 mL/min, to around 100 nm at a flow rate of 15 mL/












































































































FIGURE 7 Scale-up of polymeric nanocapsules preparation. Influence of the batch volume in the particle size and PDI of the nanocapsules (NCs)
prepared by a discontinuous procedure (a). Schematic representation of the chip used to prepare the polymeric NCs by microfluidics (b).
Increasing the flow rate produces a faster mixing of the solvent and nonsolvent phases inside the channels, leading to smaller NCs (c). In contrast,
increasing the concentration of the components increases the particle sizes of the resulting nanosystems (d)
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where we illustrated the influence of the addition rate of the organic
phase over the aqueous phase in the NCs particle size. The PDI was
maintained at around 0.3, which is slightly higher than the PDI of the
batch production. The ζ-potential was highly positive (> +40 mV) in all
cases. As expected, the particle size also increased as the concentra-
tion of the phases increased (Figure 7d). Finally, high concentrations
(22.5 mg/mL) also produced polydispersed systems, which lead,
finally, to aggregation.
In comparison with the batch mode, to produce 1 L of NCs using
microfluidics, 10 cartridges working in parallel would take 40 min with
a flow rate of 2.5 mL/min, and only 7 min for 15 mL/min. These
values give an idea of the utility and feasibility of microfluidics for the
scale-up of NCs.
4 | CONCLUSIONS
Here we show the versatility of the polymeric NCs delivery platform
in terms of physicochemical properties and composition. In particular,
NCs with one or multiple polymer layers and different surface charge
can be produced with a tuneable size ranging from 50 nm to 500 nm,
approximately. Importantly, these NCs can be produced by the
solvent-displacement technique using a minimum amount of ethanol,
thus precluding the need for its elimination. In addition, the prepara-
tion can be miniaturized and adapted to a HTS procedure, and scaled-
up using a batch mode, or in a continuous process using microfluidics.
This information is particularly relevant as a forward step toward scal-
ing the formation of NCs from bench to clinic.
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